02043QAB3

Alnylam Pharmaceuticals, Inc.

Could not find a ticker for this position, may be a filing error

A biopharmaceutical company that makes RNAi therapeutics — medicines that "silence" disease-causing genes — with six marketed drugs including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO for rare conditions like ATTR amyloidosis. Founded in 2002 by Nobel laureate Phillip Sharp and fellow scientists, its name comes from Alnilam, the bright center star of Orion's belt, chosen as an "aspirational North Star" for genomic medicine. Its ONPATTRO was the first RNAi drug ever approved by the FDA, in 2018.

1.00% Convertible Senior Notes due September 15, 2027